New Insights on Management of Acute Lymphoblastic Leukemia in the Contemporary Era
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 163
Special Issue Editor
Special Issue Information
Dear Colleagues,
Acute lymphoblastic leukemia (ALL) is commonly seen in children and tends to have an excellent outcome. In adults, it is more challenging to treat due to inherent resistance to conventional cytotoxic therapies and frequent relapses and suboptimal tolerance to intensive chemotherapy especially in elderly with high morbidity and mortality. Over the last decade, we have seen improvement in the outcomes of adult with ALL by incorporating newer antibody constructs, including antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell (CAR T-cell) therapies. We have seen significant improvements in the outcome of Philadelphia chromosome positive (Ph+) B-cell ALL with the incorporation of potent BCR-ABL1 tyrosine kinase inhibitor (TKI) combinations, and now, patients are able to achieve better and more durable responses with an improvement in long-term outcome. We have also seen advancement in our ability to assess response to therapy with the use of extremely sensitive measurable residual disease assays including clonoSEQ and next-generation sequencing (NGS), which have helped in our treatment approach. While the outcome of patients with B-cell ALL has improved, we continue to face challenges in managing T-cell ALL especially the one associated with relapsed disease. In this issue, we will highlight the current status of ALL management by focusing on challenges and opportunities.
Dr. Talha Badar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- B-cell ALL
- T-cell ALL
- MRD in ALL
- Ph+ve ALL
- CAR T-cells
- NGS-MRD
- menin inhibitors
- blinatumomab
- inotuzumab
- ponatinib
- BCR-ABL1
- TKI
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
